危重患者中使用依托咪酯与死亡风险的关联:与氯胺酮的比较
该研究基于Premier医疗数据库2008至2021年间接受有创机械通气的ICU患者,比较了机械通气启动当日使用依托咪酯与氯胺酮患者的院内死亡率。在倾向性评分匹配的22,273对患者中,依托咪酯组院内死亡率为21.6%,氯胺酮组为18.7%,调整后OR为1.28(95%CI 1.21-1.34),且该关联不受后续糖皮质激素治疗影响。
要点
- 机械通气启动当日使用依托咪酯与较氯胺酮更高的院内死亡风险相关(调整OR 1.28,95%CI 1.21-1.34)。
- 绝对风险差异为2.8%(95%CI 2.1%-3.6%),依托咪酯组死亡率21.6% vs 氯胺酮组18.7%。
- 后续使用糖皮质激素未减弱依托咪酯与死亡率的关联。
核心结论
- 在危重患者中,机械通气启动当日使用依托咪酯与较氯胺酮更高的院内死亡几率相关,且该关联独立于后续糖皮质激素治疗。
研究设计与样本
- 基于Premier医疗数据库2008至2021年的回顾性队列研究,纳入接受有创机械通气的ICU患者,采用多变量回归和倾向性评分匹配比较依托咪酯与氯胺酮。
- 共1,689,945例接受有创机械通气的患者,其中738,855例(43.7%)使用了依托咪酯;在住院前2天内接受机械通气的患者中,建立22,273对匹配患者。
主要发现
- 在主要分析中,依托咪酯组院内死亡率为21.6%,氯胺酮组为18.7%,绝对风险差异2.8%(95%CI 2.1%-3.6%),调整OR 1.28(95%CI 1.21-1.34)。
- 该关联在各亚组和敏感性分析中保持一致。
- 后续使用糖皮质激素未减弱依托咪酯与死亡率之间的关联。
临床怎么用
- 对于危重患者机械通气启动时的镇静诱导,需权衡依托咪酯与氯胺酮的死亡风险差异。
- 依托咪酯的使用与较高的院内死亡率相关,临床决策时应考虑替代药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Uncertainty remains regarding the risks associated with single-dose use of etomidate. Objectives: To assess the use of etomidate in critically ill patients and compare outcomes for patients who received etomidate versus ketamine. Methods: We assessed patients who received invasive mechanical ventilation (IMV) and were admitted to an ICU in the Premier Healthcare Database between 2008 and 2021. The exposure was receipt of etomidate on the day of IMV initiation, and the main outcome was hospital mortality. Using multivariable regression, we compared patients who received IMV within the first 2 days of hospitalization who received etomidate with propensity score-matched patients who received ketamine. We also assessed whether receipt of corticosteroids in the days after intubation modified the association between etomidate and mortality. Measurements and Main Results: Of 1,689,945 patients who received IMV, nearly half (738,855; 43.7%) received etomidate. Among those who received IMV in the first 2 days of hospitalization, we established 22,273 matched pairs administered either etomidate or ketamine. In the primary analysis, receipt of etomidate was associated with greater hospital mortality relative to ketamine (21.6% vs. 18.7%; absolute risk difference, 2.8%; 95% confidence interval, 2.1%, 3.6%; adjusted odds ratio, 1.28, 95% confidence interval, 1.21,1.34). This was consistent across subgroups and sensitivity analyses. We found no attenuation of the association with mortality with receipt of corticosteroids in the days after etomidate use. Conclusions: Use of etomidate on the day of IMV initiation is common and associated with a higher odds of hospital mortality than use of ketamine. This finding is independent of subsequent treatment with corticosteroids.
引用
- Wunsch H, Bosch NA, Law AC, et al. Evaluation of Etomidate Use and Association with Mortality Compared with Ketamine among Critically Ill Patients. Am J Respir Crit Care Med. 2024. PMID: 39173173. doi:10.1164/rccm.202404-0813OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。